BCL2 and prostate carcinoma: In conclusion, it was demonstrated that a novel small-molecule inhibitor of the anti-apoptotic Bcl-2 family proteins, apogossypol, had significant anti‐tumor activity in vitro and in vivo in prostate cancers.